# Thierry Frébourg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thierry-frebourg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,962 |
| Field | Genetic factors in colorectal cancer |
| h-index | 90 |
| i10-index | 304 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5021709517 |
| ORCID iD | 0000-0003-0399-4007 |
| Works | 499 |

## Researcher papers

Showing 12 of 13.

- [<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1](https://scholariq.org/papers/i-lmo2-i-associated-clonal-t-cell-proliferation-in-two-patients-after-gene/)
- [APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy](https://scholariq.org/papers/app-locus-duplication-causes-autosomal-dominant-early-onset-alzheimer-disease/)
- [Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability](https://scholariq.org/papers/integrative-analyses-of-colorectal-cancer-show-immunoscore-is-a-stronger/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma](https://scholariq.org/papers/somatic-and-germline-activating-mutations-of-the-alk-kinase-receptor-in/)
- [Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation](https://scholariq.org/papers/revised-diagnostic-criteria-for-neurofibromatosis-type-1-and-legius-syndrome-an/)
- [Early-Onset Autosomal Dominant Alzheimer Disease: Prevalence, Genetic Heterogeneity, and Mutation Spectrum](https://scholariq.org/papers/early-onset-autosomal-dominant-alzheimer-disease-prevalence-genetic/)
- [Revisiting Li-Fraumeni Syndrome From <i>TP53</i> Mutation Carriers](https://scholariq.org/papers/revisiting-li-fraumeni-syndrome-from-i-tp53-i-mutation-carriers/)
- [Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy](https://scholariq.org/papers/clinical-relevance-of-kras-mutation-detection-in-metastatic-colorectal-cancer/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice/)
- [Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome](https://scholariq.org/papers/cancer-screening-recommendations-for-individuals-with-li-fraumeni-syndrome/)
- [Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls](https://scholariq.org/papers/contribution-to-alzheimer-s-disease-risk-of-rare-variants-in-trem2-sorl1-and/)

## Researcher topics

- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cancer-related Molecular Pathways](https://scholariq.org/topics/cancer-related-molecular-pathways/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.